

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 October 2022 (20.10.2022)



(10) International Publication Number
WO 2022/221548 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) C07K 16/30 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2022/024842

(22) International Filing Date:

14 April 2022 (14.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/174,990 14 April 2021 (14.04.2021) US

(71) Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 210 West 7th St., Austin, Texas 78701 (US).

(72) Inventors: REZVANI, Katy; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US). SHPALL, Elizabeth; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US). BASAR, Rafet; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US). DAHER, May; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US). ACHARYA, Sunil; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US). UPRETY, Nadima; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US). NUNEZ CORTES, Ana Karen; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US). ENSLEY, Emily; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US). MARIN COSTA, David; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US).

(74) Agent: SISTRUNK, Melissa L.; Norton Rose Fulbright US LLP, 1301 McKinney, Suite 5100, Houston, Texas 77010-3095 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: CHIMERIC ANTIGEN RECEPTORS TO TARGET CD5-POSITIVE CANCERS

(57) Abstract: Embodiments of the disclosure include methods and compositions related to targeting of CD5-expressing cells with particular engineered receptors. In specific embodiments, NK cells are specifically engineered to bind the CD5 antigen using particular chimeric antigen receptor constructs. In certain embodiments, vectors that express the CD5-targeting CARs also express particular a suicide gene and/or one or more particular cytokines.



WO 2022/221548 A1